5 free lookup(s). No credit card required.

If you need more lookups, subscriptions start at $34 USD/month.

Board Member @ (October 2025 - Present)
CEO @ (April 2021 - Present)
Independent Pricing and Market Access Consultant @ Mark Kornfeld Consulting (October 2017 - March 2021)
Director, Pricing and Market Access @ Creativ-Ceutical (March 2015 - September 2017)
Associate Director @ (February 2013 - December 2014)
Owner @ Valena Health AB (September 2011 - January 2013)
Director Market Access and Sales @ Airsonett AB (March 2010 - August 2011)
Market Access Consultant @ Creativ-Ceutical (formerly Altipharm) (February 2004 - December 2009)
Licensing Manager @ OTL Pharma (November 2001 - January 2004)
Licensing Manager @ Orphan Europe (July 1999 - October 2001)
Consultant @ Bridgehead technologies Ltd (January 1999 - June 1999)
Health Economic Editor @ Lundbeck SA (September 1998 - December 1998)

EMAUD; University of Lyon, France
European Market Access University Diploma (Market Access)
2010-2010
Faculty of Medicine, University of Regensburg, Germany
Post Doc (Molecular Biology)
1997-1998
Dep of Physiology, Stony Brook University, USA 1996-1997
Lund University
PhD (Physiology)
1996-1997
Faculty of Medicine, University of Lund, Sweden
Ph. D. (Medical Physiology)
1992-1997
Faculty of Natural Sciences, University of Lund, Sweden
Bachelor of Science (Biology and Chemistry)
1987-1991

Mark Kornfeld, based in Stockholm, SE, is currently a CEO at Melius Pharma. Mark Kornfeld brings experience from previous roles at Aeriant Therapeutics, Mark Kornfeld Consulting, Creativ-Ceutical and OptumInsight. Mark Kornfeld holds a 2010 - 2010 European Market Access University Diploma in Market Access @ EMAUD; University of Lyon, France. With a robust skill set that includes Orphan Drugs, Market Access, Market Research, Pharmaceutical Industry, Pharmaceutics and more. Mark Kornfeld has 2 emails and 1 mobile phone numbers on RocketReach.